Correlation of Titer of Antibody to Principal Neutralizing Domain of HIVMNStrain with Disease Progression in Japanese Hemophiliacs Seropositive for HIV Type 1
- 1 March 1997
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 13 (4) , 317-326
- https://doi.org/10.1089/aid.1997.13.317
Abstract
With the use of the principal neutralizing determinant (PND) peptide-based ELISA to measure anti-PND antibodies that specifically bound synthetic peptides derived from HIVIIIB, HIVMN, HIVRF, HIVSC, HIVWJM2, HIVAf1.con, or HIVAf2.con, type-specific antibodies to the HIVMN peptide were studied in 350 serum specimens from Japanese with hemophilia A who had been injected with known unheated factor VIII concentrates until 1985 and had been infected with HIV-1 subtype B. These antibodies were not found in any of the seronegative sera of hemophiliacs, patients with autoimmune diseases, or normal healthy controls. Further, all hemophiliacs rapidly progressing to AIDS and death among the 95 hemophiliacs in a restricted Nara area had antibody titers of less than 20 and their low levels preceded the rapid progression to the disease state. In contrast, slowly progressing hemophiliacs maintained an antibody titer of more than 100 from the initial stages of viral infection and remained asymptomatic. Sequence analysis of the V3 regions of HIV-1 indicated that the hemophiliacs who maintained a high anti-PNDMN antibody level showed a conserved MN sequence. In contrast, the HIV-infected hemophiliacs with nonreactivity in the ELISA showed sequence changes in the neutralizing epitopes of HIVMN. The dynamic of the serum anti-PNDMN antibody titer appear to be a characteristic indicator of the progression of the HIV-infected status in Japanese hemophiliacs seropositive for HIV-1.Keywords
This publication has 30 references indexed in Scilit:
- Adaptive Evolution of Human Immunodeficiency Virus-Type 1 During the Natural Course of InfectionScience, 1996
- Anti-V3 antibody reactivity correlates with clinical stage of HIV-1 infection and with serum neutralizing activityClinical and Experimental Immunology, 1995
- Transmission and Pathogenesis of Human Immunodeficiency Virus Type 1AIDS Research and Human Retroviruses, 1994
- The Reactivities of HIV-1+Human Sera with Solid-Phase V3 Loop Peptides Can Be Poor Predictors of Their Reactivities with V3 Loops on Native gp120 MoleculesAIDS Research and Human Retroviruses, 1993
- High Prevalence of Antibodies to the gp120 V3 Region Principal Neutralizing Determinant of HIV-1MNin Sera from Africa and the AmericasAIDS Research and Human Retroviruses, 1991
- Transient High Levels of Viremia in Patients with Primary Human Immunodeficiency Virus Type 1 InfectionNew England Journal of Medicine, 1991
- Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160Nature, 1990
- Possible Beneficial Effects of Neutralizing Antibodies and Antibody-Dependent, Cell-Mediated Cytotoxicity in Human Immunodeficiency Virus InfectionAIDS Research and Human Retroviruses, 1990
- A LONGITUDINAL STUDY ON SEROCONVERSION OF HTLV‐III/LAV IN JAPANESE HAEMOPHILIACSBritish Journal of Haematology, 1987
- Characterization of Serum Netralization Response to the Human Immunodeficiency Virus (HIV)AIDS Research and Human Retroviruses, 1987